Skip to content

Prevention of Atrial Fibrillation by Optimized Overdrive Stimulation

Prevention of Atrial Fibrillation by Optimized Overdrive Stimulation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01912326
Acronym
PAFOS
Enrollment
249
Registered
2013-07-31
Start date
2002-07-31
Completion date
2008-04-30
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Bradycardia

Keywords

pacemaker, atrial fibrillation

Brief summary

Evaluation of dynamic Atrial Overdrive Stimulation using the AF Suppression Algorithm to prevent atrial tachyarrhythmias in patients with more than 2% Auto Mode Switch Episodes with optimized pacemaker programming. Hypothesis: Dynamic atrial Overdrive (AF Suppression) reduces AT/AF Burden by 30% as compared to programming DDDR-(60) without AF Suppression when all other parameters are optimized.

Detailed description

Atrial Fibrillation is the most common Heart Rhythm Disorder requiring therapy.

Interventions

DEVICEPacemaker Implantation

Implantation of a dual chamber pacemaker

Sponsors

Abbott Medical Devices
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* indication for dual chamber pacemaker * documented paroxysmal or persistent Atrial Fibrillation * P-wave \>1.0 mV in Sinus Rhythm or sufficient detection of AFib * stable antyarrhythmic therapy * age \>= 19 years * written informed consent * implantation of a Identity DR 5370/5376 or later * bipolar atrial lead

Exclusion criteria

* permanent AFib * reversible etiology of AFib * HYHA II or IV * Coronary Artery disease with stable angina pectoris * implanted ICD or planned implantation of a ICD * cardiac surgery within the last 6 months or planned within 12 months * live expectancy \< 12 months * pregnancy

Design outcomes

Primary

MeasureTime frame
Reduction of AT/AF Burden in the pacemaker diagnostics12 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026